imatinib mesylate has been researched along with Erythrocytosis in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Anshu, A; Das, R; Jamwal, M; Lad, D; Rathore, S; Sreedharanunni, S; Virk, H | 1 |
| Betticher, DC; Cornea, MI; Levrat, E; Pugin, P | 1 |
| Bonfigli, S; Dore, F; Fozza, C; Longu, F; Pardini, S | 1 |
| Bourla, MH; Feldman, EJ; Fruchtman, S; Salvado, AJ; Silver, RT; Spivak, JL; Vandris, K | 1 |
| Antonescu, CR; Besmer, P; Bosbach, B; de Stanchina, E; Deshpande, S; Manova-Todorova, K; Moore, MA; Rossi, F; Scandura, JM; Shieh, JH; Sommer, G; Veach, DR | 1 |
| Birgens, H; Bjerrum, OW; Clausen, NT; Hansen, PB; Hasselbalch, HC; Jensen, BA; Ralfkiaer, E; Therkildsen, MH | 1 |
| Bernhardt, B; Peerschke, EI; Silver, RT; Varon, D; Weksler, BB; Yin, W | 1 |
| Dan, K; Inami, M; Inokuchi, K; Kosaka, F; Mitamura, Y; Okabe, M; Yamaguchi, H | 1 |
1 trial(s) available for imatinib mesylate and Erythrocytosis
| Article | Year |
|---|---|
Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukocytosis; Male; Middle Aged; Piperazines; Polycythemia; Primary Myelofibrosis; Pyrimidines; Thrombocytosis; Treatment Outcome | 2003 |
7 other study(ies) available for imatinib mesylate and Erythrocytosis
| Article | Year |
|---|---|
Imatinib responsive erythrocytosis in a patient with FIP1L1::PDGFRA rearranged myeloid neoplasm with hypereosinophilia - Another manifestation of a stem cell neoplasm.
Topics: Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Myeloproliferative Disorders; Neoplasms; Oncogene Proteins, Fusion; Polycythemia; Stem Cells | 2022 |
BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.
Topics: Aged; Chronic Disease; Diagnosis, Differential; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Polycythemia; Polycythemia Vera; Protein Kinase Inhibitors | 2015 |
Isolated polyglobulia as an uncommon presentation of chronic myeloid leukaemia.
Topics: Aged; Antineoplastic Agents; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Polycythemia | 2016 |
Treatment of polycythemia vera with imatinib mesylate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Polycythemia; Polycythemia Vera; Prognosis; Pyrimidines; Thrombocytosis | 2012 |
Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Lineage; Dasatinib; Disease Models, Animal; Drug Resistance; Drug Resistance, Neoplasm; Erythrocytes; Exons; Gastrointestinal Stromal Tumors; Imatinib Mesylate; Mice; Mutation; Phenotype; Piperazines; Polycythemia; Proto-Oncogene Proteins c-kit; Pyrimidines; Thiazoles | 2012 |
Examination of platelet function in whole blood under dynamic flow conditions with the cone and plate(let) analyzer: effect of erythrocytosis and thrombocytosis.
Topics: Benzamides; Blood Flow Velocity; Blood Platelets; Hematocrit; Humans; Imatinib Mesylate; Piperazines; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Polycythemia; Pyrimidines; Quinazolines; Thrombocytosis; Time Factors | 2007 |
Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Polycythemia; Pyrimidines | 2007 |